Involvement of IFN regulatory factor (IRF)-1 and IRF-2 in the formation and progression of human esophageal cancers

Cancer Research

Volumn 67, Issue 6, 2007, Pages 2535-2543

  Wang, Yan ^a   Liu, Dong Ping ^a   Chen, Ping Ping ^a,b   Koeffler, H Phillip ^c   Tong, Xiang Jun ^a,d   Xie, Dong ^a,e  

^a UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

^b ZHENGZHOU UNIVERSITY   (China)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d PEKING UNIVERSITY   (China)

^e INSTITUTE OF GEOLOGY AND GEOPHYSICS   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR 1; HISTONE H4; INTERFERON REGULATORY FACTOR 1; INTERFERON REGULATORY FACTOR 2; PROTEIN BCL 2; SMALL INTERFERING RNA;

ADULT; AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CARCINOGENICITY; CELL PROLIFERATION; CELLULAR DISTRIBUTION; CLINICAL ARTICLE; CONTROLLED STUDY; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; TUMOR DIFFERENTIATION;

ANIMALS; APOPTOSIS; CELL GROWTH PROCESSES; DISEASE PROGRESSION; ESOPHAGEAL NEOPLASMS; ESOPHAGUS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERFERON REGULATORY FACTOR-1; INTERFERON REGULATORY FACTOR-2; MALE; MICE; MICE, NUDE; MIDDLE AGED; RNA, MESSENGER; TRANSFECTION; TRANSPLANTATION, HETEROLOGOUS;

EID: 34047270775     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-3530     Document Type: Article

References (49)

1. Sato F, Shimada Y, Selaru FM, et al. Prediction of survival in patients with esophageal carcinoma using artificial neural networks. Cancer 2005;103:1596-605.
2. Lu SH. Alterations of oncogenes and tumor suppressor genes in esophageal cancer in China. Mutat Res 2000; 462:343-53.
3. Xing D, Tan W, Lin D. Genetic polymorphisms and susceptibility to esophageal cancer among Chinese population [review]. Oncol Rep 2003;10:1615-23.
4. Ogasawara S, Tamura G, Maesawa C, et al. Common deleted region on the long arm of chromosome 5 in esophageal carcinoma. Gastroenterology 1996;110:52-7.
5. Nguyen H, Hiscott J, Pitha PM. The growing family of interferon regulatory factors. Cytokine Growth Factor Rev 1997;8:293-312.
6. Barnes B, Lubyova B, Pitha PM. On the role of IRF in host defense. J Interferon Cytokine Res 2002;22:59-71.
7. Lohoff M, Mak TW. Roles of interferon-regulatory factors in T-helper-cell differentiation. Nat Rev Immunol 2005;5:125-35.
8. Tanaka N, Taniguchi T. The interferon regulatory factors and oncogenesis. Semin Cancer Biol 2000;10: 73-81.
9. Taniguchi T, Ogasawara K, Takaoka A, Tanaka N. IRF family of transcription factors as regulators of host defense. Annu Rev Immunol 2001;19:623-55.
10. Harada H, Kitagawa M, Tanaka N, et al. Antioncogenic and oncogenic potentials of interferon regulatory factors-1 and -2. Science 1993;259:971-4.
11. Fujita T, Reis LF, Watanabe N, Kimura Y, Taniguchi T, Vilcek J. Induction of the transcription factor IRF-1 and interferon-β mRNAs by cytokines and activators of second-messenger pathways. Proc Natl Acad Sci U S A 1989;86:9936-40.
12. Yim JH, Ro SH, Lowney JK, Wu SJ, Connett J, Doherty GM. The role of interferon regulatory factor-1 and interferon regulatory factor-2 in IFN-γ growth inhibition of human breast carcinoma cell lines. J Interferon Cytokine Res 2003;23:501-11.
13. Tanaka N, Ishihara M, Kitagawa M, et al. Cellular commitment to oncogene-induced transformation or apoptosis is dependent on the transcription factor IRF-1. Cell 1994;77:829-39.
14. Lowney JK, Boucher LD, Swanson PE, Doherty GM. Interferon regulatory factor-1 and -2 expression in human melanoma specimens. Ann Surg Oncol 1999;6: 604-8.
15. Connett JM, Badri L, Giordano TJ, Connett WC, Doherty GM. Interferon regulatory factor 1 (IRF-1) and IRF-2 expression in breast cancer tissue microarrays. J Interferon Cytokine Res 2005;25:587-94.
16. Moriyama Y, Nishiguchi S, Tamori A, et al. Tumor-suppressor effect of interferon regulatory factor-1 in human hepatocellular carcinoma. Clin Cancer Res 2001; 7:1293-8.
17. Giatromanolaki A, Koukourakis MI, Ritis K, Mimidis K, Sivridis E. Interferon regulatory factor-1 (IRF-1) suppression and derepression during endometrial tumorigenesis and cancer progression. Cytokine 2004;26: 164-8.
18. Watson GA, Queiroz de Oliveira PE, Stang MT, et al. Ad-IRF-I induces apoptosis in esophageal adenocarcinoma Neoplasia 2006;8:31-7.
19. Pan QQ. Studies on esophageal cancer cells in vitro. Proc Chin Acad Med Sci Peking Union Med Coll 1989;4: 52-7.
20. Jiang W, Zhang YJ, Kahn SM, et al. Altered expression of the cyclin D1 and retinoblastoma genes in human esophageal cancer. Proc Natl Acad Sci U S A 1993;90: 9026-30.
21. Xie D, Nakachi K, Wang H, Elashoff R, Koeffler HP. Elevated levels of connective tissue growth factor, WISP-1, and CYR61 in primary breast cancers associated with more advanced features. Cancer Res 2001;61:8917-23.
22. Chow WA, Fang JJ, Yee JK. The IFN regulatory factor family participates in regulation of Fas ligand gene expression in T cells. J Immunol 2000;164:3512-8.
23. Qin XF, An DS, Chen IS, Baltimore D. Inhibiting HIV-1 infection in human T cells by lentiviral-mediated delivery of small interfering RNA against CCR5. Proc Natl Acad Sci U S A 2003;100:183-8.
24. Xie D, Yin D, Tong X, et al. Cyr61 is overexpressed in gliomas and involved in integrin-linked kinase-mediated Akt and p-catenin-TCF/Lef signaling pathways. Cancer Res 2004;64:1987-96.
25. Coccia EM, Del Russo N, Stellacci E, et al. Activation and repression of the 2-5A synthetase and p21 gene promoters by IRF-1 and IRF-2. Oncogene 1999;18:2129-37.
26. Vaughan PS, van der Meijden CM, Aziz F, et al. Cell cycle regulation of histone H4 gene transcription requires the oncogenic factor IRF-2. J Biol Chem 1998; 273:194-9.
27. Nguyen H, Mustafa A, Hiscott J, Lin R. Transcription factor IRF-2 exerts its oncogenic phenotype through the DNA binding/transcription repression domain. Oncogene 1995;11:537-44.
28. Eksteen JA, Scott PA, Perry I, Jankowski JA. Inflammation promotes Barrett's metaplasia and cancer: a unique role for TNFα. Eur J Cancer Prev 2001;10:163-6.
29. Pawelec G. Tumour escape: antitumour effectors too much of a good thing? Cancer Immunol Immunother 2004;53:262-74.
30. 1/S phase transition. J Cell Physiol 1998;177:453-64.
31. Aziz F, van Wijnen AJ, Vaughan PS, et al. The integrated activities of IRF-2 (HiNF-M), CDP/cut (HiNF-D) and H4TF-2 (HiNF-P) regulate transcription of a cell cycle controlled human histone H4 gene: mechanistic differences between distinct H4 genes. Mol Biol Rep 1998;25:1-12.
32. Wang C, Fu M, Mani S, Waaler S, Senderowicz AM, Pestell RG. Histone acetylation and the cell-cycle in cancer. Front Biosci 2001;6:D610-29.
33. Yu JT, Foster RG, Dean DC. Transcriptional repression by RB-E2F and regulation of anchorage-independent survival. Mol Cell Biol 2001;21:3325-35.
34. Sherr CJ. Cancer cell cycles. Science 1996;274:1672-7.
35. Chan SL, Yu VC. Proteins of the bcl-2 family in apoptosis signalling: from mechanistic insights to therapeutic opportunities. Clin Exp Pharmacol Physiol 2004;31:119-28.
36. Oakes SA, Lin SS, Bassik MC. The control of endoplasmic reticulum-initiated apoptosis by the BCL-2 family of proteins. Curr Mol Med 2006;6:99-109.
37. Kluck RM, Bossy-Wetzel E, Green DR, Newmeyer DD. The release of cytochrome c from mitochondria: a primary site for Bcl-2 regulation of apoptosis. Science 1997;275:1132-6.
38. Yang J, Liu X, Bhalla K, et al. Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked. Science 1997;275:1129-32.
39. Anayama T, Furihata M, Takeuchi T, et al. Insufficient effect of p27(KIP1) to inhibit cyclin D1 in human esophageal cancer in vitro. Int J Oncol 2001;18:151-5.
40. Nagasawa S, Onda M, Sasajima K, et al. Cyclin D1 overexpression as a prognostic factor in patients with esophageal carcinoma. J Surg Oncol 2001;78:208-14.
41. Ohbu M, Saegusa M, Kobayashi N, et al. Expression of bcl-2 protein in esophageal squamous cell carcinomas and its association with lymph node metastasis. Cancer 1997;79:1287-93.
42. Dormond O, Lejeune FJ, Ruegg C. Modulation of cdk2, cyclin D1, p16INK4a, p21WAF and p27Kip1 expression in endothelial cells by TNF/IFN γ. Anticancer Res 2002;22:3159-63.
43. Naldini A, Carney DH, Pucci A, Carraro F. Human α-thrombin stimulates proliferation of interferon-γ differentiated, growth-arrested U937 cells, overcoming differentiation-related changes in expression of p21CIP1/WAF1 and cyclin D1. J Cell Physiol 2002; 191:290-7.
44. Burchert A, Cai D, Hofbauer LC, et al. Interferon consensus sequence binding protein (ICSBP; IRF-8) antagonizes BCR/ABL and down-regulates bcl-2. Blood 2004;103:3480-9.
45. Stephanou A, Brar BK, Knight RA, Latchman DS. Opposing actions of STAT-1 and STAT-3 on the Bcl-2 and Bcl-x promoters. Cell Death Differ 2000;7:329-30.
46. Romeo G, Fiorucci G, Chiantore MV, Percario ZA, Vannucchi S, Affabris E. IRF-1 as a negative regulator of cell proliferation. J Interferon Cytokine Res 2002;22: 39-47.
47. Dotto GP. p21(WAF1/Cip1): more than a break to the cell cycle? Biochim Biophys Acta 2000;1471:M43-56.
48. Lehrbach DM, Nita ME, Cecconello I. Molecular aspects of esophageal squamous cell carcinoma carcinogenesis. Arq Gastroenterol 2003;40:256-61.
49. Watanabe N, Sakakibara J, Hovanessian AG, Taniguchi T, Fujita T. Activation of IFN-β element by IRF-1 requires a posttranslational event in addition to IRF-1 synthesis. Nucleic Acids Res 1991;19:4421-8.